Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FLQ-104
- Development stage
- Preclinical
- Lead developer
- FELIQS
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
FLQ-104 is a first-in-class small molecule drug in preclinical development by FELIQS for the treatment of intermediate dry age-related macular degeneration (dry AMD) and potentially other eye diseases. The compound acts as an inhibitor of lipid peroxidation and ferroptosis, two processes implicated in retinal cell death and disease progression in geographic atrophy and dry AMD. FELIQS developed FLQ-104 using its proprietary screening platform targeting lipid oxidation/ferroptosis pathways, aiming to provide earlier intervention for patients with dry AMD. The drug is designed for oral administration, offering a convenient route compared to current therapies[1][2][8].
Beyond the preview
Go deeper on FLQ-104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FLQ-104.